Clinical Trial Update: Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating nivolumab and ipilimumab in combination with immunogenic chemotherapy for patients with advanced non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Hatim Husain | Conditions: Advanced NSCLC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING